{"title":"Cholecystectomy in a man with hemophilia A and inhibitor on emicizumab prophylaxis: A case report","authors":"Paula Cella Giacometto , Marcello Tortelli Bavaresco , Juliana Alvares-Teodoro , Ricardo Mesquita Camelo","doi":"10.1016/j.htct.2022.10.003","DOIUrl":"10.1016/j.htct.2022.10.003","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137922014584/pdfft?md5=0fd2b41668263029adbdcf01526f4071&pid=1-s2.0-S2531137922014584-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10738488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2022.11.011
Maria Luiza Rocha da Rosa Borges , João Lucas Cruz Souza , Luiz Henrique Rodrigues , Maria Teresa Marquim Nogueira Cornélio , Ana Claudia dos Anjos , Neide Santos , Terezinha de Jesus Marques Salles
Introduction
Fanconi anemia (FA) is a rare autosomal recessive disease characterized by chromosomal instability and increased predisposition to malignancy. The diagnosis of FA requires clinical evaluation, confirmation of chromosomal fragility and/or analysis of genetic mutations. Therefore, this study aims to identify the clinical profile of patients with FA in the state of Pernambuco, Brazil.
Method
We analyzed 100 individuals referred from the major hematology and bone marrow (BM) transplant centers in the state of Pernambuco, Brazil, between the years 2018 and 2022. The diagnosis of FA was performed using the mitomycin C chromosomal fragility test, clinical data and classical and molecular cytogenetic analyses.
Results
We enrolled a total of 16 patients with FA to comprise this study. Most of these individuals (87.5%) came from the Agreste and Sertão regions of Pernambuco. We observed a slight female prevalence of FA (1.3:1). The primary clinical and laboratory findings were café au lait spots (62.5%) and bone abnormalities (53%, mainly thumb deformities [40%]). We performed BM cytogenetic analysis for eight patients – seven showed no chromosomal abnormalities and one presented the karyotype 47,XY,+21 [15].
Conclusions
Our results are important to promote public health measures for the early diagnosis of FA, as well as to foster the engagement of a multidisciplinary group in the treatment of this disease.
导言范可尼贫血症（Fanconi anemia，FA）是一种罕见的常染色体隐性遗传病，其特点是染色体不稳定和易患恶性肿瘤。诊断范可尼贫血症需要进行临床评估、染色体脆性确认和/或基因突变分析。因此，本研究旨在确定巴西伯南布哥州 FA 患者的临床特征：我们分析了2018年至2022年间从巴西伯南布哥州主要血液学和骨髓（BM）移植中心转诊的100名患者。使用丝裂霉素 C 染色体脆性试验、临床数据以及经典和分子细胞遗传学分析对 FA 进行诊断：本研究共招募了 16 名 FA 患者。其中大部分患者（87.5%）来自伯南布哥州的阿格里斯特和塞尔唐地区。我们观察到，FA 的女性发病率略高于男性（1.3:1）。主要的临床和实验室检查结果是咖啡斑（62.5%）和骨骼异常（53%，主要是拇指畸形[40%]）。我们对 8 名患者进行了 BM 细胞遗传学分析，其中 7 人未发现染色体异常，1 人的核型为 47,XY,+21 [15]：我们的研究结果对于促进早期诊断 FA 的公共卫生措施，以及促进多学科小组参与该疾病的治疗具有重要意义。
{"title":"Clinical and cytogenetic profile of Fanconi anemia diagnosed after implementation of mitomycin C cytogenetic test in the state of Pernambuco, Brazil","authors":"Maria Luiza Rocha da Rosa Borges , João Lucas Cruz Souza , Luiz Henrique Rodrigues , Maria Teresa Marquim Nogueira Cornélio , Ana Claudia dos Anjos , Neide Santos , Terezinha de Jesus Marques Salles","doi":"10.1016/j.htct.2022.11.011","DOIUrl":"10.1016/j.htct.2022.11.011","url":null,"abstract":"<div><h3>Introduction</h3><p>Fanconi anemia (FA) is a rare autosomal recessive disease characterized by chromosomal instability and increased predisposition to malignancy. The diagnosis of FA requires clinical evaluation, confirmation of chromosomal fragility and/or analysis of genetic mutations. Therefore, this study aims to identify the clinical profile of patients with FA in the state of Pernambuco, Brazil.</p></div><div><h3>Method</h3><p>We analyzed 100 individuals referred from the major hematology and bone marrow (BM) transplant centers in the state of Pernambuco, Brazil, between the years 2018 and 2022. The diagnosis of FA was performed using the mitomycin C chromosomal fragility test, clinical data and classical and molecular cytogenetic analyses.</p></div><div><h3>Results</h3><p>We enrolled a total of 16 patients with FA to comprise this study. Most of these individuals (87.5%) came from the <em>Agreste</em> and <em>Sertão</em> regions of Pernambuco. We observed a slight female prevalence of FA (1.3:1). The primary clinical and laboratory findings were <em>café au lait</em> spots (62.5%) and bone abnormalities (53%, mainly thumb deformities [40%]). We performed BM cytogenetic analysis for eight patients – seven showed no chromosomal abnormalities and one presented the karyotype 47,XY,+21 [15].</p></div><div><h3>Conclusions</h3><p>Our results are important to promote public health measures for the early diagnosis of FA, as well as to foster the engagement of a multidisciplinary group in the treatment of this disease.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137923000019/pdfft?md5=052c84ea5295771c6fd5239bd1f83804&pid=1-s2.0-S2531137923000019-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2024.02.012
Marcelo Bellesso , Alice Bianco , Rodrigo Santucci , Renato Torrescasana Centrone , Iohanã Gabriely Costa Oliveira , Adelson Alves
{"title":"REALM study: A retrospective evaluation of treatment patterns in patients with mantle cell lymphoma in a routine single private practice in Brazil","authors":"Marcelo Bellesso , Alice Bianco , Rodrigo Santucci , Renato Torrescasana Centrone , Iohanã Gabriely Costa Oliveira , Adelson Alves","doi":"10.1016/j.htct.2024.02.012","DOIUrl":"10.1016/j.htct.2024.02.012","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924000555/pdfft?md5=2ba3511b2250cb7a0e0c3240137fb86c&pid=1-s2.0-S2531137924000555-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140272488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2023.10.001
Gisele dos Santos Barros, Carla Vaneska Fernandes Leal, Lauro Augusto Caetano Leite, Denys Eiti Fujimoto, Rodolfo Delfini Cançado
Introduction
Sickle cell disease (SCD) is an inherited and multisystem blood disorder characterized by hemolytic anemia, vaso-occlusive crises (VOCs), progressive multiorgan damage and increased mortality. In Brazil, it is one of the most common monogenic diseases afflicting 60,000 to 100,000 individuals, however, there are sparse epidemiological data, as well as information on the utilization of public healthcare resources. Method: This was a 5-year (2016 - 2020) retrospective study conducted at one Brazilian reference center on SCD - Santa Casa de Sao Paulo, in Sao Paulo, Brazil.
Results
Among a total of 100 eligible adult patients, the median age was 31.0 years old, 84% of the patients were aged between 18 and 45 years old; 59% were women and 91% presented the genotype HbSS. The number of hematologist and non-hematologist visits at the outpatient unit were 2,198 and 1,436, respectively. The number of hospital ER visits was 758, of which 51% required 864 days of hospitalization. The main cause for seeking hospital medical care was the VOCs. The numbers and ratios of VOCs were: 1 to 10 VOCs, 64%; 11 to 20, 15%, and; 21 or more, 1%. There was a statistically significant difference between the number of VOCs and hospitalizations, as well as infection. Conclusion: Results indicate the burden of SCD on Brazilian patients’ daily lives, the impact of VOCs on public healthcare resources, the importance of having a national surveillance program to improve resource utilization and clinical outcomes of patients with SCD and the urgent need for the revitalizing of the current national comprehensive SCD care programs.
{"title":"Real-world evidence of the burden of sickle cell disease: a 5-year longitudinal study at a Brazilian reference center","authors":"Gisele dos Santos Barros, Carla Vaneska Fernandes Leal, Lauro Augusto Caetano Leite, Denys Eiti Fujimoto, Rodolfo Delfini Cançado","doi":"10.1016/j.htct.2023.10.001","DOIUrl":"10.1016/j.htct.2023.10.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Sickle cell disease (SCD) is an inherited and multisystem blood disorder characterized by hemolytic anemia, vaso-occlusive crises (VOCs), progressive multiorgan damage and increased mortality. In Brazil, it is one of the most common monogenic diseases afflicting 60,000 to 100,000 individuals, however, there are sparse epidemiological data, as well as information on the utilization of public healthcare resources. Method: This was a 5-year (2016 - 2020) retrospective study conducted at one Brazilian reference center on SCD - Santa Casa de Sao Paulo, in Sao Paulo, Brazil.</p></div><div><h3>Results</h3><p>Among a total of 100 eligible adult patients, the median age was 31.0 years old, 84% of the patients were aged between 18 and 45 years old; 59% were women and 91% presented the genotype HbSS. The number of hematologist and non-hematologist visits at the outpatient unit were 2,198 and 1,436, respectively. The number of hospital ER visits was 758, of which 51% required 864 days of hospitalization. The main cause for seeking hospital medical care was the VOCs. The numbers and ratios of VOCs were: 1 to 10 VOCs, 64%; 11 to 20, 15%, and; 21 or more, 1%. There was a statistically significant difference between the number of VOCs and hospitalizations, as well as infection. Conclusion: Results indicate the burden of SCD on Brazilian patients’ daily lives, the impact of VOCs on public healthcare resources, the importance of having a national surveillance program to improve resource utilization and clinical outcomes of patients with SCD and the urgent need for the revitalizing of the current national comprehensive SCD care programs.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137923025890/pdfft?md5=461316b9ab064103194e8d5447f18f17&pid=1-s2.0-S2531137923025890-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139295505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2023.01.003
Mariana Guarana, Marcio Nucci
Introduction
Infection is a serious complication among patients with hematologic malignancies (HMs) and in hematopoietic cell transplant (HCT) recipients. In most centers, the management of these complications is provided by the hematologist in person, thus demanding a knowledge of basic aspects of infection.
Methods
To evaluate the knowledge of the hematologist on infections, we invited clinicians to answer two questionnaires with 20 multiple-choice questions covering epidemiology, prophylaxis, diagnosis and treatment of infection in patients with HMs and HCT.
Results
We obtained 289 answers: 223 in survey 1 (febrile neutropenia) and 66 in survey 2 (infection in HCT). The median score was 5.0 in both surveys (range 0.5 - 9.0). In survey 1, the questions with the lowest number of correct answers were Q3 (8%), concerning the cefepime dose, and Q1 (9%), which asked about the epidemiologic link between the use of high dose cytarabine and viridans streptococcal bacteremia. In survey 2, two questions about cytomegalovirus (CMV) infection had the lowest percentage of correct answers (Q4, 12% and Q11, 18%). Clinicians attending to HCT recipients had higher scores, compared to clinicians attending to patients with HM only (median score of 5.0 and 4.5, p = 0.03, in survey 1 and 6.0 and 4.5, p = 0.001, in survey 2). In both surveys staff clinicians, residents and professors had similar scores.
Conclusion
This is the first study in Brazil assessing the knowledge of hematologists on infectious complications. The low median score overall indicates an urgent need for continuous education. Such initiatives will eventually result in better patient care.
{"title":"Evaluation of the knowledge of hematologists about the management of infectious complications in hematologic patients","authors":"Mariana Guarana, Marcio Nucci","doi":"10.1016/j.htct.2023.01.003","DOIUrl":"10.1016/j.htct.2023.01.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Infection is a serious complication among patients with hematologic malignancies (HMs) and in hematopoietic cell transplant (HCT) recipients. In most centers, the management of these complications is provided by the hematologist in person, thus demanding a knowledge of basic aspects of infection.</p></div><div><h3>Methods</h3><p>To evaluate the knowledge of the hematologist on infections, we invited clinicians to answer two questionnaires with 20 multiple-choice questions covering epidemiology, prophylaxis, diagnosis and treatment of infection in patients with HMs and HCT.</p></div><div><h3>Results</h3><p>We obtained 289 answers: 223 in survey 1 (febrile neutropenia) and 66 in survey 2 (infection in HCT). The median score was 5.0 in both surveys (range 0.5 - 9.0). In survey 1, the questions with the lowest number of correct answers were Q3 (8%), concerning the cefepime dose, and Q1 (9%), which asked about the epidemiologic link between the use of high dose cytarabine and viridans streptococcal bacteremia. In survey 2, two questions about cytomegalovirus (CMV) infection had the lowest percentage of correct answers (Q4, 12% and Q11, 18%). Clinicians attending to HCT recipients had higher scores, compared to clinicians attending to patients with HM only (median score of 5.0 and 4.5, <em>p</em> = 0.03, in survey 1 and 6.0 and 4.5, <em>p</em> = 0.001, in survey 2). In both surveys staff clinicians, residents and professors had similar scores.</p></div><div><h3>Conclusion</h3><p>This is the first study in Brazil assessing the knowledge of hematologists on infectious complications. The low median score overall indicates an urgent need for continuous education. Such initiatives will eventually result in better patient care.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137923000287/pdfft?md5=11a4b01a7a1d5470b0763d36910caa5c&pid=1-s2.0-S2531137923000287-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10694910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2024.01.004
Josiane Garcia , Anna Cecília Dias Maciel Carneiro , Sheila Soares Silva , Karla Fabiana Nunes da Silva , Joilson Meneguci , Helio Moraes-Souza
Background
Blood transfusion is an effective therapeutic practice. However, even adopting all procedures for transfusion safety, there are risks, one of which is immediate adverse reactions. The aim of this study was, by active search, to evaluate the occurrence of immediate adverse reactions estimating the occurrence rate within the first 24 h.
Methods
An exploratory, descriptive, prospective study with quantitative analysis was carried out of patients undergoing surgery who received blood component transfusions during hospitalization from October 2018 to August 2019. Data on blood component request forms were collected from the transfusion agency by reviewing medical records and interviewing the patient or family members. Descriptive statistics and the chi-square test were used to analyze the association of demographic variables with the presence or absence of transfusion reactions.
Results
A total of 1042 blood component units were transfused in 393 transfusions performed on 184 patients. The main transfused blood component was packed red blood cells. Seventeen reactions were identified in the medical records, using the active search method, none of which had been reported. The transfusion reaction rate was 16.3 occurrences per 1000 transfused units, while the notification rate for the 9389 blood component units transfused by the transfusion agency in the study period was 3.83/1000. There was no statistically significant association between the occurrences or not of transfusion reactions and demographic variables.
Conclusion
Through the active search method, it was possible to observe the underreporting of adverse reactions, showing inadequate compliance with current legislation, which is essential to minimize errors and increase transfusion safety.
{"title":"Underreporting of transfusion incidents","authors":"Josiane Garcia , Anna Cecília Dias Maciel Carneiro , Sheila Soares Silva , Karla Fabiana Nunes da Silva , Joilson Meneguci , Helio Moraes-Souza","doi":"10.1016/j.htct.2024.01.004","DOIUrl":"10.1016/j.htct.2024.01.004","url":null,"abstract":"<div><h3>Background</h3><p>Blood transfusion is an effective therapeutic practice. However, even adopting all procedures for transfusion safety, there are risks, one of which is immediate adverse reactions. The aim of this study was, by active search, to evaluate the occurrence of immediate adverse reactions estimating the occurrence rate within the first 24 h.</p></div><div><h3>Methods</h3><p>An exploratory, descriptive, prospective study with quantitative analysis was carried out of patients undergoing surgery who received blood component transfusions during hospitalization from October 2018 to August 2019. Data on blood component request forms were collected from the transfusion agency by reviewing medical records and interviewing the patient or family members. Descriptive statistics and the chi-square test were used to analyze the association of demographic variables with the presence or absence of transfusion reactions.</p></div><div><h3>Results</h3><p>A total of 1042 blood component units were transfused in 393 transfusions performed on 184 patients. The main transfused blood component was packed red blood cells. Seventeen reactions were identified in the medical records, using the active search method, none of which had been reported. The transfusion reaction rate was 16.3 occurrences per 1000 transfused units, while the notification rate for the 9389 blood component units transfused by the transfusion agency in the study period was 3.83/1000. There was no statistically significant association between the occurrences or not of transfusion reactions and demographic variables.</p></div><div><h3>Conclusion</h3><p>Through the active search method, it was possible to observe the underreporting of adverse reactions, showing inadequate compliance with current legislation, which is essential to minimize errors and increase transfusion safety.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924000348/pdfft?md5=b7e19853052b4dbf885bdbad8c0134d9&pid=1-s2.0-S2531137924000348-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2024.04.065
Fernanda Ferreira Mendonça , Alice Santos de Miranda , Henrique Massao Achidate Makino , Lorena Marinelli Mendes , Danielle Vieira Sobral , Marycel Figols de Barboza , Luciana Malavolta , Leonardo Lima Fuscaldi
Introduction/Justification
Peptides are implicated in various physiological responses and hold significant potential as targeting molecules, especially in cancer diagnosis or treatment. Radiolabeled peptides have been investigated for their potential as theranostic agents, holding considerable promise for precisely targeting tumorigenic cells. Previous studies indicate that biologically active peptides exhibit a high affinity for the Epidermal Growth Factor receptor (EGFr), which is overexpressed in various tumor cells, including glioblastoma, the most prevalent and aggressive malignant brain tumor.
Objectives
To evaluate the in vitro interactions involving two radiolabeled peptide inhibitors targeting the EGFr overexpressed in glioblastoma cells.
Materials and Methods
Two EGFr-targeting peptide inhibitors, anti-EGFr-LP and anti-EGFr-LG, were radiolabeled with [131I]NaI (11.1–14.8 MBq) using the chloramine T method (room temperature; reaction time = 120 s). The radiochemical yield (RCY) (n = 8) and stability (n = 3) were evaluated using ascending chromatography on TLC-SG strips and acetonitrile/water (95:5) as eluent. C6 and U-87 MG glioblastoma cell lines were cultured in supplemented DMEM medium (5% CO2 atmosphere; 37°C) until reaching ∼85% confluence. Subsequently, aliquots of 2 x 10^6 C6 or U-87 MG cells were incubated with each radiopeptide (37°C) under agitation (500 rpm). In vitro binding and internalization percentages were assessed at 1 and 3 h post-incubation (n = 6). Data were expressed as ‘mean ± standard deviation’ and the statistical analysis was performed using GraphPad Prism software.
Results
The RCY of [131I]I-anti-EGFr-LP and [131I]I-anti-EGFr-LG were 92.92 ± 3.42 and 97.80 ± 1.08, respectively. Both 131I-labeled peptides were radiochemically stable over 24 h. The in vitro interaction between C6 cells and [131I]I-anti-EGFr-LP showed binding percentages of 4.80 ± 0.37% (1 h) and 5.87±1.21% (3 h), with no statistically significant difference (p = 0.1519). The internalization percentages, within the bound fractions, increased from 64.45 ± 4.19% (1 h) to 75.15±1.60% (3 h) (p < 0.0001). For the [131I]I-anti-EGFr-LG, the data were of the same order of magnitude. The binding percentages increased from 3.95±0.33% (1 h) to 6.03 ± 0.66 (3 h) (p < 0.0001) and the internalization percentages, among the bound fractions, were 62.57±5.53% (1 h) and 64.04±3.21% (3 h), with no statistically significant difference (p = 0.5959). The in vitro interaction between U-87 MG cells and [131I]I-anti-EGFr-LP showed an increment of the binding percentages from 6.50 ± 0.93% (1 h) to 8.03 ± 0.29% (3 h) (p < 0.0001), but the internalization percentages, within the bound fractions, showed no statistically significant difference (p = 0.2791), 68.98 ± 2.23% (1 h) and 73.02±6.57% (3 h). For the [131I]I-anti-EGFr-LG, the binding percentages were 10.97±1.48 (1 h) and
{"title":"ASSESSMENT OF IN VITRO INTERACTIONS BETWEEN RADIOLABELED EGFR-TARGETING PEPTIDE INHIBITORS AND GLIOBLASTOMA CELLS","authors":"Fernanda Ferreira Mendonça , Alice Santos de Miranda , Henrique Massao Achidate Makino , Lorena Marinelli Mendes , Danielle Vieira Sobral , Marycel Figols de Barboza , Luciana Malavolta , Leonardo Lima Fuscaldi","doi":"10.1016/j.htct.2024.04.065","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.065","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Peptides are implicated in various physiological responses and hold significant potential as targeting molecules, especially in cancer diagnosis or treatment. Radiolabeled peptides have been investigated for their potential as theranostic agents, holding considerable promise for precisely targeting tumorigenic cells. Previous studies indicate that biologically active peptides exhibit a high affinity for the Epidermal Growth Factor receptor (EGFr), which is overexpressed in various tumor cells, including glioblastoma, the most prevalent and aggressive malignant brain tumor.</p></div><div><h3>Objectives</h3><p>To evaluate the in vitro interactions involving two radiolabeled peptide inhibitors targeting the EGFr overexpressed in glioblastoma cells.</p></div><div><h3>Materials and Methods</h3><p>Two EGFr-targeting peptide inhibitors, anti-EGFr-LP and anti-EGFr-LG, were radiolabeled with [131I]NaI (11.1–14.8 MBq) using the chloramine T method (room temperature; reaction time = 120 s). The radiochemical yield (RCY) (n = 8) and stability (n = 3) were evaluated using ascending chromatography on TLC-SG strips and acetonitrile/water (95:5) as eluent. C6 and U-87 MG glioblastoma cell lines were cultured in supplemented DMEM medium (5% CO2 atmosphere; 37°C) until reaching ∼85% confluence. Subsequently, aliquots of 2 x 10^6 C6 or U-87 MG cells were incubated with each radiopeptide (37°C) under agitation (500 rpm). In vitro binding and internalization percentages were assessed at 1 and 3 h post-incubation (n = 6). Data were expressed as ‘mean ± standard deviation’ and the statistical analysis was performed using GraphPad Prism software.</p></div><div><h3>Results</h3><p>The RCY of [131I]I-anti-EGFr-LP and [131I]I-anti-EGFr-LG were 92.92 ± 3.42 and 97.80 ± 1.08, respectively. Both 131I-labeled peptides were radiochemically stable over 24 h. The in vitro interaction between C6 cells and [131I]I-anti-EGFr-LP showed binding percentages of 4.80 ± 0.37% (1 h) and 5.87±1.21% (3 h), with no statistically significant difference (p = 0.1519). The internalization percentages, within the bound fractions, increased from 64.45 ± 4.19% (1 h) to 75.15±1.60% (3 h) (p < 0.0001). For the [131I]I-anti-EGFr-LG, the data were of the same order of magnitude. The binding percentages increased from 3.95±0.33% (1 h) to 6.03 ± 0.66 (3 h) (p < 0.0001) and the internalization percentages, among the bound fractions, were 62.57±5.53% (1 h) and 64.04±3.21% (3 h), with no statistically significant difference (p = 0.5959). The in vitro interaction between U-87 MG cells and [131I]I-anti-EGFr-LP showed an increment of the binding percentages from 6.50 ± 0.93% (1 h) to 8.03 ± 0.29% (3 h) (p < 0.0001), but the internalization percentages, within the bound fractions, showed no statistically significant difference (p = 0.2791), 68.98 ± 2.23% (1 h) and 73.02±6.57% (3 h). For the [131I]I-anti-EGFr-LG, the binding percentages were 10.97±1.48 (1 h) and ","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001470/pdfft?md5=f166ece239c4ea2821e8f81522f5bd2a&pid=1-s2.0-S2531137924001470-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2024.04.080
Tobias Luis dos Reis, Kaique Moraes do Amaral, Najua Abou Arab, Maria Emilia Seren Takahashi, José Barreto Campello Carvalheira, Barbara Juarez Amorim, Elba Cristina Sá de Camargo Etchebehere, Mariana da Cunha Lopes de Lima, Allan de Oliveira Santos, Ludmila Santiago Almeida, Eliana Cristina Martins Miranda, Carmen Silvia Passos Lima, Celso Dario Ramos, Sérgio Querino Brunetto, Simone Kuba, NAtália Tobar, Carmino Antonio Souza, Mariana Cortês Caleffi, Mariana Fernandes França Mitre Amorim
Introduction/Justification
Recently, the tracer Prostate Specific Membrane Antigen (PSMA), which can be labeled with the radioisotopes 68Ga or 18F, has been commercially introduced. Theoretically, as the name suggests, it is a substance specific to the membrane of prostate cells and prostate cancer. However, several studies have shown that it is also a marker of neoangiogenesis, leading to its uptake in various other neoplasms and benign diseases.
Objectives
This study aims to evaluate the utility of radiolabeled PSMA in detecting desmoid tumors, comparing it to 18F-luorodeoxyglucose (FDG).
Materials and Methods
Three participants with a confirmed diagnosis of desmoid tumor underwent PET/CT examinations with 18F-PSMA and 18F-FDG, with a maximum interval of 3 days between examinations. Images were visually compared lesion by lesion and the maximum standardized uptake value (SUV) was calculated for each lesion and each radiopharmaceutical.
Results
All lesions presented uptake of both 68Ga-PSMA and 18F-FDG. In the first patient, 3 lesions were identified: a mass adjacent to the pancreas measuring 5.4 cm (FDG: SUV = 2.0) (PSMA: SUV = 8.2), a mass in the right iliac fossa measuring 7.7 cm (FDG: SUV = 3.8) (PSMA: SUV = 5.7), and another involving the duodenojejunal transition measuring 4.1 cm (FDG: SUV = 1.9) (PSMA: SUV = 3.7). In the second patient, a mass was identified adjacent to the head and uncinate process of the pancreas measuring 9.2 cm (FDG: SUV = 9.8) (PSMA: SUV = 6.1). In the third patient, an irregular retroperitoneal mass was identified at the level of the aortic bifurcation (FDG: SUV = 2.3) (PSMA: SUV = 2.4).
Conclusion
Desmoid tumors can demonstrate uptake of both 68Ga-PSMA and 18F-FDG. The intensity of tracer uptake in the lesions is variable, with some showing greater uptake of FDG, others of PSMA, suggesting a potential complementary role for these radiotracers in desmoid tumors.
{"title":"COMPARISON OF 68GA-PSMA AND 18F-FDG-PET/CT IN THE ASSESSMENT OF DESMOID TUMORS","authors":"Tobias Luis dos Reis, Kaique Moraes do Amaral, Najua Abou Arab, Maria Emilia Seren Takahashi, José Barreto Campello Carvalheira, Barbara Juarez Amorim, Elba Cristina Sá de Camargo Etchebehere, Mariana da Cunha Lopes de Lima, Allan de Oliveira Santos, Ludmila Santiago Almeida, Eliana Cristina Martins Miranda, Carmen Silvia Passos Lima, Celso Dario Ramos, Sérgio Querino Brunetto, Simone Kuba, NAtália Tobar, Carmino Antonio Souza, Mariana Cortês Caleffi, Mariana Fernandes França Mitre Amorim","doi":"10.1016/j.htct.2024.04.080","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.080","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Recently, the tracer Prostate Specific Membrane Antigen (PSMA), which can be labeled with the radioisotopes 68Ga or 18F, has been commercially introduced. Theoretically, as the name suggests, it is a substance specific to the membrane of prostate cells and prostate cancer. However, several studies have shown that it is also a marker of neoangiogenesis, leading to its uptake in various other neoplasms and benign diseases.</p></div><div><h3>Objectives</h3><p>This study aims to evaluate the utility of radiolabeled PSMA in detecting desmoid tumors, comparing it to 18F-luorodeoxyglucose (FDG).</p></div><div><h3>Materials and Methods</h3><p>Three participants with a confirmed diagnosis of desmoid tumor underwent PET/CT examinations with 18F-PSMA and 18F-FDG, with a maximum interval of 3 days between examinations. Images were visually compared lesion by lesion and the maximum standardized uptake value (SUV) was calculated for each lesion and each radiopharmaceutical.</p></div><div><h3>Results</h3><p>All lesions presented uptake of both 68Ga-PSMA and 18F-FDG. In the first patient, 3 lesions were identified: a mass adjacent to the pancreas measuring 5.4 cm (FDG: SUV = 2.0) (PSMA: SUV = 8.2), a mass in the right iliac fossa measuring 7.7 cm (FDG: SUV = 3.8) (PSMA: SUV = 5.7), and another involving the duodenojejunal transition measuring 4.1 cm (FDG: SUV = 1.9) (PSMA: SUV = 3.7). In the second patient, a mass was identified adjacent to the head and uncinate process of the pancreas measuring 9.2 cm (FDG: SUV = 9.8) (PSMA: SUV = 6.1). In the third patient, an irregular retroperitoneal mass was identified at the level of the aortic bifurcation (FDG: SUV = 2.3) (PSMA: SUV = 2.4).</p></div><div><h3>Conclusion</h3><p>Desmoid tumors can demonstrate uptake of both 68Ga-PSMA and 18F-FDG. The intensity of tracer uptake in the lesions is variable, with some showing greater uptake of FDG, others of PSMA, suggesting a potential complementary role for these radiotracers in desmoid tumors.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001627/pdfft?md5=53e6be174c7c157d57b2e357f3192c6e&pid=1-s2.0-S2531137924001627-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2024.04.081
Juliana Carron , Daniele Daiane Affonso , Suelen Aparecida Ribeiro Souza , Ana Maria Castro Ferreira , João Ernesto Carvalho , Ana Lucia Tasca Gois Ruiz , Gabriella Fraiji Melo , Flávio Lopes Alves , Leonardo Lima Fuscaldi , Luciana Malavolta , Carmen Silvia Passos Lima
Introduction/Justification
Head and neck squamous cell carcinoma (HNSCC) represents a serious health problem worldwide. Approximately 75% of patients with HNSCC have locally advanced disease at diagnosis, and the therapy for those cases involves chemoradiation or induction chemotherapy, in which cisplatin is included despite of its substantial side effects. FAPESP-founded “Cancer Innovation Center with Emphasis on Metals and Theranostics” (CancerThera) is dedicated to the development of new metallopharmaceuticals and radiopharmaceuticals for tumor diagnosis and treatment. Among these developments, an anti-integrin peptide modified by a conventional spacer (C6) and chelator (DOTA) was evaluated as a potential treatment of HNSCC. Overexpressed in HNC, integrins are transmembrane proteins that play essential roles in cell proliferation and migration. Therefore, integrin inhibition may be a potential targeted therapy for HNC patients.
Objectives
The study aimed to evaluate the effects of the DOTA-C6-anti-integrin peptide on HNSCC cell lines proliferation and migration, as an initial step for HNSCC theranostic development.
Materials and Methods
The anti-proliferative activity of the DOTA-C6-anti-integrin peptide (0.01nM - 100µM) was assessed against FaDu and SCC-25 cells by considering the cell amounts at baseline and 48h after exposure (two untreated control groups). All cells were fixed with 50% trichloroacetic acid and stained with sulforhodamine B. Spectrophotometric absorbance was performed at 540nm in a microplate reader. Cell migration was assessed in FaDu cells and FaDu cells treated with the DOTA-C6-anti-integrin peptide (1, 10, and 100µM) using the wound-healing assay. Wound cells were photographed immediately (0h) and after 16h, 24h, and 40h. Images were analyzed by the ImageJ software (National Institutes of Health). For statistical analysis, samples did assume normal distribution in Shapiro-Wilk's test, thus we used t test to compare the groups using SPSS 21 software (SPSS Incorporation).
Results
At the tested concentration range, the DOTA-C6-anti-integrin peptide did not affect proliferation of FaDu or SCC-25 cells. In FaDu cells, the DOTA-C6-anti-integrin peptide significantly (p < 0.05) inhibited migration in comparison to untreated cells, independent on sample concentration (1, 10, and 100µM) or time exposure (16, 24, or 40 h).
Conclusion
Despite the lack of anti-proliferative effect, the DOTA-C6-anti-integrin peptide inhibited migration in FaDu cells. As cell migration is an important process in HNSCC progression, our data present preliminary evidence that the DOTA-C6-anti-integrin may be used in development of theranostic agents for HNSCC.
Acknowledgements
The study was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Cien
导言/理由头颈部鳞状细胞癌（HNSCC）是全球严重的健康问题。约 75% 的 HNSCC 患者在确诊时已是局部晚期，这些病例的治疗方法包括化学放疗或诱导化疗，尽管顺铂具有很大的副作用，但仍被纳入其中。FAPESP 成立的 "以金属和放射治疗为重点的癌症创新中心"（CancerThera）致力于开发用于肿瘤诊断和治疗的新型金属药物和放射药物。在这些研发成果中，一种由传统间隔物（C6）和螯合剂（DOTA）修饰的抗整合素肽被评估为治疗 HNSCC 的潜在药物。在 HNC 中过度表达的整合素是一种跨膜蛋白，在细胞增殖和迁移中发挥着重要作用。本研究旨在评估 DOTA-C6 抗整合素肽对 HNSCC 细胞株增殖和迁移的影响，作为 HNSCC 治疗药物开发的第一步。材料与方法评估 DOTA-C6 抗整合素肽（0.01nM - 100µM）对 FaDu 和 SCC-25 细胞的抗增殖活性时，考虑了基线和暴露 48 小时后的细胞量（两组未经处理的对照组）。所有细胞均用 50%的三氯乙酸固定，并用磺胺多巴胺 B 染色。使用伤口愈合试验评估 FaDu 细胞和经 DOTA-C6 抗整合素肽（1、10 和 100µM）处理的 FaDu 细胞的细胞迁移。立即（0 小时）以及 16、24 和 40 小时后对伤口细胞进行拍照。图像由 ImageJ 软件（美国国立卫生研究院）分析。结果在测试浓度范围内，DOTA-C6-抗整合素肽不影响 FaDu 或 SCC-25 细胞的增殖。在 FaDu 细胞中，与未处理的细胞相比，DOTA-C6-抗整合素肽显著抑制了细胞迁移（p < 0.05），这与样品浓度（1、10 和 100µM）或暴露时间（16、24 或 40 小时）无关。由于细胞迁移是 HNSCC 进展的一个重要过程，我们的数据初步证明 DOTA-C6 抗整合素可用于 HNSCC 治疗药物的开发。致谢本研究得到了Coordenação de Aperfeiçoamento de Pessoal de Nívele Superior (CAPES)、Conselho Nacional de Desenvolvimento Científico e Tecnológico（CNP #429463/2018-9）、Fundação de Apoio ao Ensino e à Pesquisa do Estado de São Paulo（FAPESP #2023/09738-4、FAPESP #2023/012810-9, Cancer Theranostics Innovation Center, (CancerThera), CEPID FAPESP #2021/10265-8），以及国际原子能机构（IAEA）拉丁美洲国家发展技术合作项目（IAEA/TCLAC：EX-BRA6033-2401375）。
{"title":"INFLUENCE OF A CONVENTIONAL CHELATOR-MODIFIED ANTI-INTEGRIN PEPTIDE ON PROLIFERATION AND MIGRATION OF HEAD AND NECK CANCER CELLS","authors":"Juliana Carron , Daniele Daiane Affonso , Suelen Aparecida Ribeiro Souza , Ana Maria Castro Ferreira , João Ernesto Carvalho , Ana Lucia Tasca Gois Ruiz , Gabriella Fraiji Melo , Flávio Lopes Alves , Leonardo Lima Fuscaldi , Luciana Malavolta , Carmen Silvia Passos Lima","doi":"10.1016/j.htct.2024.04.081","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.081","url":null,"abstract":"<div><h3>Introduction/Justification</h3><p>Head and neck squamous cell carcinoma (HNSCC) represents a serious health problem worldwide. Approximately 75% of patients with HNSCC have locally advanced disease at diagnosis, and the therapy for those cases involves chemoradiation or induction chemotherapy, in which cisplatin is included despite of its substantial side effects. FAPESP-founded “Cancer Innovation Center with Emphasis on Metals and Theranostics” (CancerThera) is dedicated to the development of new metallopharmaceuticals and radiopharmaceuticals for tumor diagnosis and treatment. Among these developments, an anti-integrin peptide modified by a conventional spacer (C6) and chelator (DOTA) was evaluated as a potential treatment of HNSCC. Overexpressed in HNC, integrins are transmembrane proteins that play essential roles in cell proliferation and migration. Therefore, integrin inhibition may be a potential targeted therapy for HNC patients.</p></div><div><h3>Objectives</h3><p>The study aimed to evaluate the effects of the DOTA-C6-anti-integrin peptide on HNSCC cell lines proliferation and migration, as an initial step for HNSCC theranostic development.</p></div><div><h3>Materials and Methods</h3><p>The anti-proliferative activity of the DOTA-C6-anti-integrin peptide (0.01nM - 100µM) was assessed against FaDu and SCC-25 cells by considering the cell amounts at baseline and 48h after exposure (two untreated control groups). All cells were fixed with 50% trichloroacetic acid and stained with sulforhodamine B. Spectrophotometric absorbance was performed at 540nm in a microplate reader. Cell migration was assessed in FaDu cells and FaDu cells treated with the DOTA-C6-anti-integrin peptide (1, 10, and 100µM) using the wound-healing assay. Wound cells were photographed immediately (0h) and after 16h, 24h, and 40h. Images were analyzed by the ImageJ software (National Institutes of Health). For statistical analysis, samples did assume normal distribution in Shapiro-Wilk's test, thus we used t test to compare the groups using SPSS 21 software (SPSS Incorporation).</p></div><div><h3>Results</h3><p>At the tested concentration range, the DOTA-C6-anti-integrin peptide did not affect proliferation of FaDu or SCC-25 cells. In FaDu cells, the DOTA-C6-anti-integrin peptide significantly (p < 0.05) inhibited migration in comparison to untreated cells, independent on sample concentration (1, 10, and 100µM) or time exposure (16, 24, or 40 h).</p></div><div><h3>Conclusion</h3><p>Despite the lack of anti-proliferative effect, the DOTA-C6-anti-integrin peptide inhibited migration in FaDu cells. As cell migration is an important process in HNSCC progression, our data present preliminary evidence that the DOTA-C6-anti-integrin may be used in development of theranostic agents for HNSCC.</p></div><div><h3>Acknowledgements</h3><p>The study was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Cien","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001639/pdfft?md5=db3766de1d322b0fde90001f291daf37&pid=1-s2.0-S2531137924001639-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.htct.2024.04.073
Yuri Aguillera Pedreira , Leonardo Fonseca Monteiro do Prado , Marcelo Moreira da Silva , Mario Olimpio de Menezes , Dionisio Nepomuceno Viviani , Bruno Russiano de Oliveira Boeno , Carla Lima Santos Viviani
Introdução/Justificativa
Existem mais de 200 tipos de HPV no mundo, sendo 14 deles cancerígenos. Destes, os tipos 16 e 18 são responsáveis por 70% dos cânceres de colo de útero e lesões pré-cancerosas. Também podem provocar câncer em vagina, ânus, vulva, pênis e orofaringe. Em 2020, foram diagnosticados 602 mil novos casos de câncer cervical em todo o mundo, com 342 mil mortes. No Brasil, a mortalidade pela doença ente 1980 e 2020 foi de 165.087.2 O exame de PET-CT com Fluorodesoxiglicose marcada com F-18 (PET-CT 18F-FDG) pode ser fundamental para elucidação diagnóstica, estadiamento e acompanhamento de pacientes nos diferentes estágios da doença, trazendo maior acurácia e a possibilidade de detecção e localização de metástases.
Objetivos
No Brasil, os dados oficiais revelam que cerca de 35% dos casos de câncer de colo uterino ainda são diagnosticados nas fases III e IV, ou seja, em doença avançada, sendo que a partir da fase III existe disseminação linfonodal pélvica ou para-aórtica. Diante disso, o objetivo deste estudo foi a avaliação do panorama dos exames de PET-CT 18F-FDG realizados em uma instituição privada com a indicação de câncer de colo uterino e verificar se os dados coletados são condizentes com os dados encontrados na realidade brasileira.
Materiais e Métodos
Este estudo foi realizado utilizando-se o banco de dados de uma instituição privada. Buscados exames de PET-CT 18F-FDG com a indicação de neoplasia de colo uterino no período de 01.01.2019 a 31.08.2023. Identificados 183 estudos, sendo 36 excluídos por duplicidade e/ou indicação incorreta, permanecendo, no final, 147 exames para análise.
Resultados
Quando avaliados por indicação, a grande maioria dos exames incluídos neste estudo foram realizados para avaliação de resposta (56,5%), seguidos de estadiamento (18,4%), suspeita de recidiva (15,6%) e seguimento (9,5%). Avaliando apenas os exames de estadiamento, a grande maioria apresentava doença avançada e apenas 3,6% tiveram exame negativo. 10,7% das pacientes possuíam doença nos estágios iniciais (menor que IIIB), 10,7 no estágio IIIB, 17,9% no estágio IIIC1, 25% no IIIC2, sendo que 3,6% já apresentavam envolvimento de órgãos pélvicos (estágio IVA) e 28,6%, de órgãos a distância (estágio IVB). Quanto à suspeita de recidiva, este trabalho considerou 23 pacientes da amostra. Deste total, 78,3% dos exames foram positivos, 8,7% indeterminados e 13,0% negativos.
Conclusão
Os dados encontrados no nosso serviço são semelhantes aos encontrados no Brasil. As regras vigentes no nosso país não propiciam o diagnóstico precoce do câncer de colo uterino, na contramão dos protocolos atualizados nos Estados Unidos e na Europa. Não há autorização prevista para estadiamento, nem acompanhamento pelo SUS ou pelo rol da ANS. Este cenário configura sério obstáculo à detecção da doença em um estágio mais inicial, o que possivelmente pou
{"title":"PANORAMA DOS EXAMES DE PET-CT – FDG- 18F NO CÂNCER DO COLO DO ÚTERO EM UMA INSTITUIÇÃO PRIVADA DO BRASIL","authors":"Yuri Aguillera Pedreira , Leonardo Fonseca Monteiro do Prado , Marcelo Moreira da Silva , Mario Olimpio de Menezes , Dionisio Nepomuceno Viviani , Bruno Russiano de Oliveira Boeno , Carla Lima Santos Viviani","doi":"10.1016/j.htct.2024.04.073","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.073","url":null,"abstract":"<div><h3>Introdução/Justificativa</h3><p>Existem mais de 200 tipos de HPV no mundo, sendo 14 deles cancerígenos. Destes, os tipos 16 e 18 são responsáveis por 70% dos cânceres de colo de útero e lesões pré-cancerosas. Também podem provocar câncer em vagina, ânus, vulva, pênis e orofaringe. Em 2020, foram diagnosticados 602 mil novos casos de câncer cervical em todo o mundo, com 342 mil mortes. No Brasil, a mortalidade pela doença ente 1980 e 2020 foi de 165.087.2 O exame de PET-CT com Fluorodesoxiglicose marcada com F-18 (PET-CT 18F-FDG) pode ser fundamental para elucidação diagnóstica, estadiamento e acompanhamento de pacientes nos diferentes estágios da doença, trazendo maior acurácia e a possibilidade de detecção e localização de metástases.</p></div><div><h3>Objetivos</h3><p>No Brasil, os dados oficiais revelam que cerca de 35% dos casos de câncer de colo uterino ainda são diagnosticados nas fases III e IV, ou seja, em doença avançada, sendo que a partir da fase III existe disseminação linfonodal pélvica ou para-aórtica. Diante disso, o objetivo deste estudo foi a avaliação do panorama dos exames de PET-CT 18F-FDG realizados em uma instituição privada com a indicação de câncer de colo uterino e verificar se os dados coletados são condizentes com os dados encontrados na realidade brasileira.</p></div><div><h3>Materiais e Métodos</h3><p>Este estudo foi realizado utilizando-se o banco de dados de uma instituição privada. Buscados exames de PET-CT 18F-FDG com a indicação de neoplasia de colo uterino no período de 01.01.2019 a 31.08.2023. Identificados 183 estudos, sendo 36 excluídos por duplicidade e/ou indicação incorreta, permanecendo, no final, 147 exames para análise.</p></div><div><h3>Resultados</h3><p>Quando avaliados por indicação, a grande maioria dos exames incluídos neste estudo foram realizados para avaliação de resposta (56,5%), seguidos de estadiamento (18,4%), suspeita de recidiva (15,6%) e seguimento (9,5%). Avaliando apenas os exames de estadiamento, a grande maioria apresentava doença avançada e apenas 3,6% tiveram exame negativo. 10,7% das pacientes possuíam doença nos estágios iniciais (menor que IIIB), 10,7 no estágio IIIB, 17,9% no estágio IIIC1, 25% no IIIC2, sendo que 3,6% já apresentavam envolvimento de órgãos pélvicos (estágio IVA) e 28,6%, de órgãos a distância (estágio IVB). Quanto à suspeita de recidiva, este trabalho considerou 23 pacientes da amostra. Deste total, 78,3% dos exames foram positivos, 8,7% indeterminados e 13,0% negativos.</p></div><div><h3>Conclusão</h3><p>Os dados encontrados no nosso serviço são semelhantes aos encontrados no Brasil. As regras vigentes no nosso país não propiciam o diagnóstico precoce do câncer de colo uterino, na contramão dos protocolos atualizados nos Estados Unidos e na Europa. Não há autorização prevista para estadiamento, nem acompanhamento pelo SUS ou pelo rol da ANS. Este cenário configura sério obstáculo à detecção da doença em um estágio mais inicial, o que possivelmente pou","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S253113792400155X/pdfft?md5=388cae580c40e960396f01a0813c52f7&pid=1-s2.0-S253113792400155X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号